Get the Stockscreener App
2.12
1.43%
0.02
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $2.12, with a volume of 129.95K.
It is up +1.43% in the last 24 hours and down -33.23% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.10
Open:
$2.1
24h Volume:
129.95K
Relative Volume:
0.08
Market Cap:
$102.99M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-1.5362
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
+4.93%
1M Performance:
-33.23%
6M Performance:
+5.98%
1Y Performance:
-27.55%
1-Day Range:
$2.08
$2.15
1-Week Range:
$1.96
$2.155
52-Week Range:
$1.15
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.132 | 101.45M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.87 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.11 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
386.04 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
804.29 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.20 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Sector Leaders Rotate Capital Into VCU Data Management LimitedTop Performing Stocks & Free Significant Capital Appreciation - earlytimes.in
Aug Reactions: Will Cassava Sciences Inc stock reach all time highs in 2025Market Sentiment Review & Low Volatility Stock Suggestions - moha.gov.vn
Multi Factor Analysis Ranks Ekansh Concepts Limited as Strong BuyStock Price Targets & Register for the Next Free Workshop - earlytimes.in
Quarterly Earnings: Will Cassava Sciences Inc stock see insider buyingInsider Selling & Weekly Watchlist for Hot Stocks - moha.gov.vn
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - The Malaysian Reserve
Cassava Sciences settles securities class action for $31.25 million By Investing.com - Investing.com Australia
Cassava Sciences agrees to settle long-running investor lawsuit - The Business Journals
Cassava Sciences agrees to $31.25 million settlement in securities class action By Investing.com - Investing.com Nigeria
Cassava Sciences agrees to $31.25 million settlement in securities class action - Investing.com
Cassava Sciences Agrees to Pay $31.25 Million to Settle Securities Class Action - marketscreener.com
[8-K] CASSAVA SCIENCES INC Reports Material Event | SAVA SEC FilingForm 8-K - Stock Titan
Cassava settles securities class action suit (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences settles securities class action for $31.25 million - Investing.com
Cassava announces agreement to settle securities class action litigation - marketscreener.com
Cassava Announces Agreement to Settle Securities Class Action Litigation - GlobeNewswire
Cassava Sciences Shares Plunge After FDA Intervention - AD HOC NEWS
Published on: 2025-12-22 08:32:25 - Улправда
Can Cassava Sciences Inc. stock outperform in 2025 bull marketQuarterly Portfolio Report & Low Drawdown Momentum Trade Ideas - Улправда
Why Cassava Sciences Inc. Equity Warrant stock appeals to dividend seekersWeekly Earnings Recap & Reliable Price Breakout Alerts - Улправда
How Cassava Sciences Inc. stock responds to policy changesFed Meeting & Daily Oversold Stock Bounce Ideas - Улправда
Cassava Sciences (NASDAQ:SAVA) Stock Price Down 23.9%What's Next? - MarketBeat
Will Cassava Sciences Inc. stock benefit from sector rotationQuarterly Investment Review & Real-Time Stock Price Movement Reports - Улправда
Cassava Sciences stock on track for worst day in about 9 months — what’s driving today’s selloff? - MSN
Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff? - Asianet Newsable
FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold - Benzinga
Cassava Sciences stock falls after FDA places clinical trial on hold By Investing.com - Investing.com South Africa
Cassava Sciences stock falls after FDA places clinical trial on hold - Investing.com Australia
Cassava Sciences Shares Fall Pre-Bell After FDA Clinical Hold on Simufilam Trial - marketscreener.com
Growth Value: Why Cassava Sciences Inc. Equity Warrant stock remains a top recommendationQuarterly Profit Report & Proven Capital Preservation Tips - Улправда
Cassava Sciences down on delay for epilepsy study (SAVA:NASDAQ) - Seeking Alpha
Rate Cut: How Cassava Sciences Inc. stock responds to policy changesEarnings Trend Report & AI Powered Market Trend Analysis - Улправда
Does Cassava Sciences Inc. Equity Warrant stock trade at a discount to peersDollar Strength & Entry Point Confirmation Signals - DonanımHaber
Is Cassava Sciences Inc. stock a dividend growth opportunityJuly 2025 Review & Community Driven Trade Alerts - DonanımHaber
Why Cassava Sciences Inc. Equity Warrant stock remains undervaluedPortfolio Performance Report & Weekly Return Optimization Plans - Улправда
Cassava Sciences IncOn Dec 15, FDA places full clinical hold on Cassava's trialSEC filing - marketscreener.com
Cassava Sciences receives FDA clinical hold on simufilam trial for TSC epilepsy By Investing.com - Investing.com South Africa
Cassava Sciences receives FDA clinical hold on simufilam trial for TSC epilepsy - Investing.com Nigeria
FDA Places Clinical Hold on Cassava’s Epilepsy Trial - TipRanks
Cassava Sciences Receives FDA Clinical Hold on Simufilam Trial - TradingView — Track All Markets
Published on: 2025-12-18 21:27:30 - Улправда
Cassava Sciences (NASDAQ: SAVA) details 2025 executive bonuses and simufilam TSC focus - Stock Titan
Cassava Sciences (SAVA) Stock Analysis Report | Financials & Insights - Benzinga
Cassava Sciences Submits IND Application for Simufilam - MSN
Cassava Sciences rises 10% after market close on CEO stock buy - MSN
Why Cassava Sciences Inc. Equity Warrant stock is rated strong buyDividend Hike & High Accuracy Investment Signals - Newser
Why Cassava Sciences Inc. (PX91) stock appeals to dividend investors2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - Newser
Why Cassava Sciences Inc. (PX91) stock could be next leader2025 Market Trends & Weekly Consistent Profit Watchlists - Newser
Can Cassava Sciences Inc. (PX91) stock deliver double digit returnsJuly 2025 Opening Moves & Reliable Price Action Trade Plans - Newser
How Cassava Sciences Inc. Equity Warrant stock compares to industry benchmarksPortfolio Value Summary & AI Forecasted Entry and Exit Points - Newser
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cassava Sciences Inc Stock (SAVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Nov 20 '25 |
Buy |
2.76 |
150,000 |
414,000 |
938,060 |
| Barry Richard | President & CEO |
Nov 19 '25 |
Buy |
2.75 |
73,385 |
201,809 |
788,060 |
| Cook Robert Christopher | Chief Operating & Legal Office |
Sep 30 '25 |
Buy |
2.91 |
13,725 |
39,940 |
13,725 |
| Barry Richard | President & CEO |
Sep 22 '25 |
Buy |
2.28 |
7,172 |
16,352 |
714,675 |
| Barry Richard | President & CEO |
Sep 18 '25 |
Buy |
2.24 |
190,633 |
426,424 |
660,195 |
| Barry Richard | President & CEO |
Sep 19 '25 |
Buy |
2.29 |
47,308 |
108,319 |
707,503 |
2.09%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):